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Dena R Cohen1*, Susan Todd2, Walter M Gregory1 and Julia M Brown1Abstract
Incorporating an emerging therapy as a new randomisation arm in a clinical trial that is open to recruitment would
be desirable to researchers, regulators and patients to ensure that the trial remains current, new treatments are
evaluated as quickly as possible, and the time and cost for determining optimal therapies is minimised. It may take
many years to run a clinical trial from concept to reporting within a rapidly changing drug development
environment; hence, in order for trials to be most useful to inform policy and practice, it is advantageous for them
to be able to adapt to emerging therapeutic developments. This paper reports a comprehensive literature review
on methodologies for, and practical examples of, amending an ongoing clinical trial by adding a new treatment
arm. Relevant methodological literature describing statistical considerations required when making this specific type
of amendment is identified, and the key statistical concepts when planning the addition of a new treatment arm
are extracted, assessed and summarised. For completeness, this includes an assessment of statistical
recommendations within general adaptive design guidance documents. Examples of confirmatory ongoing trials
designed within the frequentist framework that have added an arm in practice are reported; and the details of the
amendment are reviewed. An assessment is made as to how well the relevant statistical considerations were
addressed in practice, and the related implications. The literature review confirmed that there is currently no clear
methodological guidance on this topic, but that guidance would be advantageous to help this efficient design
amendment to be used more frequently and appropriately in practice. Eight confirmatory trials were identified to
have added a treatment arm, suggesting that trials can benefit from this amendment and that it can be practically
feasible; however, the trials were not always able to address the key statistical considerations, often leading to
uninterpretable or invalid outcomes. If the statistical concepts identified within this review are considered and
addressed during the design of a trial amendment, it is possible to effectively assess a new treatment arm within
an ongoing trial without compromising the original trial outcomes.
Keywords: Adding a treatment arm, Flexible design, Multi-arm multi-stage, MAMS, Adaptive design, Type I error,
Family-wise error rate, Statistical methodology, Confirmatory randomised controlled trial, Novel designBackground
Confirmatory clinical trials can take many years to run,
requiring considerable resources. During this time, evi-
dence for a new promising treatment may emerge. It
may be advantageous to incorporate the emerging treat-
ment into the ongoing trial as a new randomisation arm.
This could be done to ensure that the outcomes of tri-
als are relevant at the time of reporting, whilst benefit-
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unless otherwise stated.shortening the overall process of comparing and select-
ing experimental treatments; allowing optimal therap-
ies to be determined faster than would otherwise be
the case; and reducing costs and patient numbers. In
addition, increasing the number of experimental arms
increases the probability of a successful treatment [1].
Ongoing treatment advances are continually improv-
ing survival rates in many therapeutic areas, including,
for example, most types of cancer [2]. The Cancer Re-
search UK (CR-UK) website states that ‘50% survive 10
or more years’ in UK cancer patients. Improving survival
times are fantastic for patients, but increase challenges to
researchers in continuing to progress and further improveThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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promising treatments are continually being developed and
tested in early phase trials, and it is difficult for re-
searchers to address them in confirmatory trials in a
timely manner. It is not appropriate to wait for the results
of every promising early phase trial in order to design the
next large phase III trial since this would delay the re-
search for the currently available treatments. The ability
to add new arms to ongoing trials could help to advance
the pace of research by allowing emerging therapies to
be investigated in populations where trials already exist
without introducing competition and by reducing the
set-up time for designing a new trial.
The example in Figure 1 illustrates a recent scenario
where Treatment A was immediately available for assess-
ment in a large, confirmatory phase III trial in newly di-
agnosed chronic lymphocytic leukaemia (CLL) patients
in the UK. However, a promising Treatment B was
undergoing assessment in a phase II trial in the same
population against the same standard control group. The
phase II trial was shortly due to complete recruitment,
but required 12 months of follow-up for the outcomes.
The choice was either to delay the assessment of treat-
ment A, therefore denying patients that promising new
therapy in a trial setting and delaying the research, or
opening the phase III trial and denying treatment B the
possibility of a timely phase III investigation in that
population. Ideally, the phase III trial assessing Treatment
A would be opened now, with Treatment B incorporated
at a later time if the phase II evidence was promising.Figure 1 Scenario in which it would be beneficial to add a treatment arm
treatment arm to a phase III trial. Treatment A is to be assessed in a large p
in the same population have not yet been reported.This review investigates the addition of a new treat-
ment arm to an ongoing trial within the following scope:
the trial has already begun recruitment and the random-
isation is still open when the new treatment is added,
the trial has a confirmatory primary objective, the trial is
designed using frequentist methodology (due to the dif-
ferences in assumptions and considerations with Bayes-
ian methodology), and the entire treatment arm is new
rather than an amendment to an existing arm.
An initial literature review found only a small number
of publications that mentioned the concept of adding an
arm, and there was no comprehensive research or guid-
ance on how to do this whilst maintaining the statistical
integrity of the trial. If the amendment compromises the
statistical validity of the trial such that a primary hypoth-
esis cannot be answered, it may render the trial uneth-
ical and waste resources.
The aims of this manuscript are to summarise the
current literature regarding statistical methods and de-
sign considerations when adapting a trial by adding a
new treatment midway through recruitment and to in-
vestigate trials that have added an arm in practice and
how they addressed the statistical considerations.
Review
Methods
A comprehensive literature review was conducted to
obtain and assess all current literature regarding statis-
tical methods and design considerations when adapting an
ongoing trial by adding a new treatment arm. A protocol. Illustration of a scenario in which it would be useful to add a
hase III trial, but the results of the phase II trial assessing treatment B
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and search strategy. Search terms were defined for the fol-
lowing major electronic databases: MEDLINE (Ovid),
EMBASE (Ovid), Science Citation Index (Web of Science)
and the Cochrane Library (Wiley), each from inception.
The ProQuest database was also searched to identify fur-
ther relevant grey (unpublished) material such as disserta-
tions and theses, and conference papers. The search terms
are provided in the Appendix. The search was conducted
in November 2012, and auto alerts were set up to identify
any further literature that arose by the time of publication.
In order to identify any additional publications, searches
were performed on references, authors and citations of
directly relevant literature.
In addition, an assessment of summary, regulatory,
guidance and review documents on flexible or adaptive
designs in general was undertaken to identify method-
ologies that have been investigated and published that
may be relevant. Many of these were collaborative works
from groups of experts. They included a handbook [3],
regulatory documents [4-6], and publications from stat-
istical collaborative groups [7,8]. A search was also con-
ducted in MEDLINE to identify any further key overview
documents. Titles and abstracts were scanned for direct
relevance to general guidance or review documents, but
not including documents relating to a particular disease
or methodology. The types of adaptation and key statis-
tical considerations discussed in each document were
listed and summarised, and their relevance was deter-
mined in discussions within the research team.
Both methodological and practical publications on tri-
als that may have implemented this adaptation were
deemed relevant, if they were within scope as described
in the introduction. However, practical examples of trials
that have implemented this research idea by adding a
new treatment part way through recruitment were rarely
identified using literature searches as the design amend-
ment was not the primary aim of results publications. In
order to identify as many trials as possible, key statisti-
cians and researchers were contacted directly, and
references from relevant methodological papers were
reviewed. Twenty-two statisticians or researchers from
UK Clinical Research Collaboration (UKCRC) registered
trials units were contacted, along with six prominent
international researchers and two large UK funding bod-
ies for cancer trials. In addition, national and international
conference, workshop and forum presentations aimed to
target wide audiences of trialists in order to gain aware-
ness of further relevant trials and keep abreast of develop-
ments in this area.
Literature on the methodology of adding arms
Only seven publications were identified that discussed
any methodological considerations when adding an armto an ongoing trial. These were reviewed in detail to as-
sess and summarise the research previously carried-out
and the recommendations or methodology discussed.
Phillips et al. [8] summarise discussion points on adap-
tive designs from the Statisticians in the Pharmaceutical
Industry (PSI) Adaptive Design Expert Group. There is a
brief paragraph stating that it is possible to add new treat-
ment arms, although no details or relevant considerations
are provided. Three references are noted, one is methodo-
logical [9], one is out of scope as it is based on exploratory
dose finding endpoints [10], and the other is a practical re-
sults paper [11].
Elm et al. [12] provide a very relevant paper on ‘flex-
ible analytical methods for adding a treatment arm mid-
study to an ongoing clinical trial’, which considers adding
an independent treatment based on external consider-
ations. The main aim is to compare methods for analys-
ing continuous, normally distributed, outcome data over
the stages (before and after the amendment), accounting
for potential differences in patient cohorts. The analysis
adjusts the allocation ratio so that all three arms complete
recruitment at the same time with the same patient num-
bers, although that leads to a reduced power for the new
comparison due to the lower numbers in the concurrent
placebo control group. Three analysis methods were com-
pared using simulations, with varying assumptions around
the intra-stage correlation caused by the addition of the
new treatment. These methods were to simply pool the
data over the stages, to apply a linear model adjusting for
the design change, and to use adaptive methodology to
calculate P values separately for each stage and combine
them using combination test principles [13]. The results
showed that when there is a correlation, there is bias and
a loss of power for both comparisons when the data are
simply pooled, but particularly for the new comparison as
would be expected due to the use of non-concurrent con-
trol placebo data. In the reported scenario, the linear
model was the most powerful since there is a loss of
power associated with the use of closed testing proce-
dures, but a combination test was thought better if there
are amendments to the original trial alongside the
addition of the arm.
Sydes et al. [14] discuss ‘STAMPEDE’, an ongoing
multi-arm multi-stage (MAMS) randomised, controlled
trial, designed to be able to drop and add arms through-
out the recruitment period. The publication is not
written as a general guidance document, but presents
trial-specific methodological and practical issues. At the
time of publishing, a new research arm had been added
to the existing control and five experimental arms,
based on the parameters and targets designed at the
outset. The trial has a pragmatic design where only con-
current controls are used for comparison with the new
treatment, and since the experimental arms are not
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adjustment is made for multiplicity.
Wason et al. [15] make general recommendations for
MAMS trials, including a section on adding treatment
arms at planned interim analyses. The example is theor-
etical, based on continuous outcomes, and focuses on
strong family-wise error rate (FWER) control due to
multiple arms, that is, the probability of making any type
I errors over the trial as a whole. The discussion argues
against the use of pairwise error rates (PWER), the
probability of making a type I error within individual
comparisons within a trial, because this situation is ‘con-
ceptually quite different to running a series of separate
trials’ and strong FWER control is required for con-
firmatory claims.
Hommel [9], Posch et al. [16] and Bauer et al. [17]
mention adding an arm or hypothesis as being possible
within a flexible framework, although the primary pur-
pose of the papers are to discuss methodology for con-
trolling FWERs when various types of design adaptation
are made, usually at internal interim analyses. Methods
are based on adaptive combination test principles to
analyse the data by stage. Posch acknowledges that the
test is stringent in controlling alpha, but may give a large
penalty in terms of power, saying ‘This is the price to be
paid for the great flexibility provided by the adaptive
design’.
In addition, two text books were identified with chap-
ters that made a reference to adding an arm to an on-
going trial [3,18]. The chapters were contributed by
Hommel and Posch respectively, and contain similar
ideas to the publications discussed above.
Literature on adaptive designs in general
The assessment of summary, regulatory, guidance and
review documents on flexible or adaptive designs in gen-
eral was undertaken as described in the methods section.
In addition to the documents previously referenced
[3-8], a further 13 were identified for detailed review
from the MEDLINE search [19-31]. None of these docu-
ments discussed the addition of a trial arm. The statis-
tical considerations discussed within these documents
were summarised and assessed for relevance to this situ-
ation, and those considerations identified to have rele-
vance are included within the summary below.
Key statistical considerations when adding a treatment
arm to an ongoing trial
This literature review on methodology when adding
arms and on adaptive designs in general generated the
identification of a number of statistical considerations
with relevance when amending ongoing clinical trials by
adding a new treatment arm based on external evidence.
The main considerations identified are illustrated inFigure 2, and summarised here. This section is intended
to aid the implementation and review of this type of de-
sign amendment by summarising the main statistical is-
sues that need to be addressed, and the related views
within the literature. Each of these should be considered
on a trial by trial basis during the planning stages.Controlling error due to stage effects
The primary statistical issue in most methodological
publications discussing adaptive or flexible designs is
strong control of the FWER, the probability of making
at least one type I error over the trial as a whole. Of the
seven relevant methodological publications, all but one
(STAMPEDE [14]) focus primarily on closed-testing ana-
lysis methods, in which analysis is performed by stage,
and a combination function is used to derive an overall
test statistic, conserving the FWER. Typically in adaptive
designs, the amendment is based on interim data that
are internal to the trial being adapted, so it is necessary
to analyse by stage and use P value combination
methods in order to control the overall FWER in the
strong sense [13]. In this case, however, it is assumed
that the arm is added based on external information
with no looks at internal trial data required, and there-
fore the FWER would not be inflated due to interim
analyses.
When data are analysed over both stages combined,
there might be a stage effect bias due to the treatment
effects differing over the stages, possibly due to a shift in
patient population at the time of the amendment. This
shift could be caused by, for example, potential toxicity,
promising early efficacy data or a change in eligibility
criteria. A different treatment effect in each treatment
group could cause a treatment*stage interaction. Simply
pooling the data over stages for analysis could lead to a
biased outcome, and therefore, it may be necessary to
analyse the stages separately.
It was noted, however, that P value combination tech-
niques, whilst strongly controlling the FWER, may have
a large penalty in terms of power [16]. The power to de-
tect a treatment*stage interaction is likely to be small;
however, if there is no indication that an interaction ex-
ists in terms of statistical significance, no clinical justifi-
cation for any stage effects and no changes to eligibility,
then using P value combination methodology might be
inappropriately conservative. Elm [12] investigated the
use of a multivariate model to adjust for stage as an al-
ternative strategy, although this has not been widely dis-
cussed in the literature. They found this approach to be
more powerful compared to combination methods.
Assuming no interim data has informed the amend-
ment, P value combination methods may be overly strin-
gent, but a stage effect and treatment*stage interaction
Figure 2 Trial timeline in which an arm is added, highlighting the key statistical considerations. Illustration of a trial timeline in which an arm is
added as an amendment. The trial has two distinct stages, and the key statistical considerations are displayed.
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approach to prevent bias.
Referring to Figure 2, stage effects would only affect
the comparison for the original experimental arm (A
versus Z), since the new arm does not exist in the first
stage.Family-wise error rate control due to multiplicity
When a third arm is added to a trial, multiplicity con-
cerns are introduced due to multiple primary compari-
sons within the same trial based on a shared control
arm. There are conflicting views within the literature on
whether strong control of the FWER is needed in this
case, or whether it is adequate to control the PWER for
each experimental arm versus control. Assuming the ex-
perimental arms are independent, the primary analyses
are restricted to comparisons against control rather than
pairwise comparisons, the arms are being tested in the
same trial for only efficiency purposes, and the amend-
ment is not based on internal interim data, it has been
argued that this is analogous to running separate trials
and therefore that FWER control is not necessary
[14,32]. However, others argue that multiplicity issues
arise due to multiple use of the same control population
and that strong FWER control is a regulatory require-
ment for confirmatory claims [4,15,33]. Regulators [33,34]
advocate that strong FWER control is required in cases
where there are more than two treatment arms, which is
likely to be the safer choice for making confirmatory
claims as long as the power remains adequate. The level
of control needs to be carefully considered and justified
on a trial-by-trial basis.Non-concurrent control data
If there is a shift in the patient population in the second
stage, after the new arm has been added, the control
data collected prior to the amendment may have a dif-
ferent survival pattern to that collected after. For this
reason, the control data collected prior to the amend-
ment may not be an unbiased comparator for the new
arm. One of the methodological papers stipulates the
use of concurrent controls [14]. The others do not dis-
cuss this directly, but by advocating methods for analys-
ing the data by stage and then combining the p-values,
this is implicit.
Power recalculation
When a new treatment is included within a confirmatory
trial, care needs to be taken that there is adequate power
to assess the primary hypothesis associated with that
treatment. In addition, the literature recognises that
strong control of the FWER will reduce the power [18],
which should be accounted for to ensure that the power
remains adequate for the existing and new hypotheses.
Determinants of efficiency
The allocation ratio and length of recruitment to each
treatment arm could be adjusted to improve efficiency
in terms of total number of patients required and time
taken to answer the primary hypotheses, and need to be
carefully balanced considering the requirements for the
trial in addition to the viewpoints within the literature
described here.
Dunnett [35] showed that the optimal allocation to the
control group in multi-arm trials is approximately the
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to minimise the total numbers of patients required.
Wason et al. [15] investigated the optimal allocation ra-
tio in MAMS trials with varying numbers of experimen-
tal arms and numbers of stages, allowing for early
stopping. They found that ‘Although efficiency (in terms
of maximum sample size) can be gained by deviating
from an optimal allocation to each arm, the gain is gener-
ally fairly small’. This was due to the chance of experimen-
tal arms being dropped at each stage, suggesting that
optimal allocation is not necessarily straightforward where
the number of treatment arms varies throughout the trial.
Patient acceptability also needs to be considered, since the
more attractive a trial (often perceived as being related to
the higher the chance of receiving an experimental treat-
ment) the better recruitment rates tend to be.
Elm et al. [12] believe that the allocation ratio should
be adjusted so that all arms complete recruitment at the
same time to ensure maintenance of blinding and to
prevent a ‘stage III’ effect due to dropping the original
arm. Other trialists such as those who design MAMS tri-
als, however, advocate that arms can be added or dropped
throughout the trial at different stages as required, which
leads to a rolling design where outcomes become avail-
able for analysis at different times within different arms.
Changes to the control group
Potentially, a new therapy may receive approval, which
would make the existing control group inferior to stand-
ard of care and, therefore, unethical. No methodological
papers mention changing the control group, but for long
or rolling trials this is something that is likely to arise.
This could cause complex issues, and needs careful
consideration.
Logistical considerations
There are many important logistical considerations dis-
cussed within the literature that need to be overcome
for the amendment to be feasible. They include: funding;
time taken to implement the amendment; approvals; ac-
ceptability to funders, patients, regulators and researchers;
blinding; changes to data management systems; inter-
action with and inclusion of the Data Monitoring
Committee (DMC) and Trial Steering Committee (TSC);
centre approvals; recruitment strategy, whether to pause
or continue; and feasibility of including treatments pro-
duced by different pharmaceutical companies.
Practical examples of ongoing trials in which an arm has
been added
A search of the literature only identified three examples
of trials in which an arm had been added, two results
papers and the Sydes et al. publication, which also in-
cludes the methodological discussion [14]. However, thedirect contacts described in the Methods section sug-
gested 30 unique trials. Eight trials were identified to be
within scope. All of these trials had obtained appropri-
ate ethical approval.
Two trials have MAMS designs and six are large phase
III trials published in high-impact journals, some of
which went on to change clinical practice.
AML16 [36] and STAMPEDE [14,37,38] have MAMS
designs, each having added new arms, based on prede-
termined criteria. One arm was added to the non-intensive
randomisation for AML16 when there were three arms
already in the trial, 4 years into the 5-year recruitment
period. Publications report some pairwise comparisons
arising from this trial, but the outcomes for the new arm
have yet to be published. STAMPEDE is still open to re-
cruitment and has currently added three arms 6, 7 and
more than 8 years after the trial opened. Some of the ori-
ginal arms had closed to recruitment when the arms were
added, but the control arm remains open. All arms are still
in follow-up for their primary outcome measure.
The 2NN trial [11] was a large international HIV trial
(Lancet, 2004). The new arm became the control, and
the overall numbers were not increased thus reducing
the power for all comparisons. The authors refer to the
addition as a drawback and state that the overall efficacy
estimates should be interpreted with caution, but be-
lieve that the main conclusions of the study are robust.
CATIE [39] was a double-blind schizophrenia trial
(NEJM, 2005). A fifth arm was added after 1 year of re-
cruitment following FDA approval. Patient numbers
were not increased to the trial as a whole, and an even
allocation ratio led to approximately 50% power for the
new comparison. The trial statistician said they had ‘a
limited budget and could not add enough patients for
good power, yet it was felt by investigators that if it was
not added, then the study might be missing an import-
ant evaluation’.
SANAD [40] was an Health Technology Assessment
(HTA) funded epilepsy trial, (Lancet, 2007). An un-
planned fifth arm was added within a non-inferiority
setting but without an increase to the trial size, leading
to the conclusion for the new arm that ‘the smaller
numbers of patients available to the comparison reduce
the statistical power and we could not conclude that
they are equivalent’.
AML15 [41,42] was a complex trial where a new arm
was added to the induction randomisation, which had
a 2 x 2 factorial design. The new treatment was origin-
ally added alone, but later was amended to include the
factorial randomisation to make it a 3 x 2 design. The
results or statistical considerations when adding the
arm have not been published.
N9741 [43,44] and N0147 [45] were large, practice-
changing, US regulatory colorectal cancer trials (JCO
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ber of treatments added and dropped, although care was
taken to control the power. The final publication in-
cluded only the arms that remained after the amend-
ments had taken place.
Statistical considerations in practice
The statistical considerations that were identified within
the methodological literature have been addressed to
varying extents in practice. Note that not all consider-
ations need to be addressed in each case because of the
nature of the trials and their objectives. When designing
or critically evaluating the results of different trials, it
should be determined for each trial whether the condi-
tions are necessary for the results to be robust, or ad-
vantageous to improve efficiency or feasibility.
None of the trials analysed the results by stage, and
only one (STAMPEDE [14]) reported adjusting for stage
or treatment*stage interaction within multivariate analyses.
Of the trials that added an arm, four strongly con-
trolled the family-wise error rate for multiplicity due to
having more than one primary comparison, and four did
not, of which two were MAMS trials that primarily com-
pared each experimental arm only to control.
Seven of the eight trials used concurrently recruited
control patients only. The other (2NN [11]) tested for an
intra-stage correlation before pooling the data, although
power for this test to detect a treatment*stage inter-
action was likely to be low.
Only five of the eight trials controlled the power for the
existing and new hypotheses. The others were underpow-
ered for some or all primary comparisons due to the
amendment, and all reported this as a limitation. No tri-
als adjusted the power to account for FWER control.
Only two trials deviated from a 1:1 allocation ratio:
2NN [11] changed from its original 1:1:1 design to re-
cruit at 1:2:2:1 after the amendment for practical rea-
sons, and STAMPEDE [14] recruited more to control
initially because ‘It is more efficient to have more patients
allocated to the control arm when there are more research
arms co-recruiting’. Once some arms had been dropped
and there were fewer experimental arms, the new compar-
isons were randomised with even allocation, although the
allocation ratios remained constant within any given com-
parison. All but STAMPEDE [14] stopped recruitment at
the same time in all confirmatory arms, excluding those
that were dropped early at interim analyses.
Although none of the methodological papers men-
tioned changing the control group, two trials have done
so when adding a new arm in practice. The 2NN trial
[11] amended the primary hypotheses so the new arm
became the control group for all primary analyses. N9741
[43] changed the control group for the whole trial to one
of the existing experimental arms because of a change inthe standard of care, requiring the original control arm to
be dropped.
Conclusions
Recent initiatives in clinical trials are aimed at speeding
up research by making better use of scarce resources.
For example, the FDA’s Critical Path Initiative ‘to drive
innovation in the scientific processes through which
medical products are developed, evaluated, and manu-
factured’ included the production of guidance on adap-
tive designs to increase the efficiency of studies. In the
UK, the National Institute for Health Research Health
Technology Assessment (NIHR HTA) programme re-
cently released a call for ‘Efficient Study Designs’ with a
focus on research that ‘will demonstrate particular de-
sign features to allow either more rapid conduct, or
lower costs’. It is clear that there is the demand to im-
prove the efficiency of clinical trials in order to speed up
the overall process of getting the best therapies to
patients. If a suitable treatment emerges whilst a trial in
a similar population is ongoing, there would be many
advantages to modifying the existing trial by adding the
new arm, as long as the statistical considerations are ad-
dressed appropriately.
This literature review has confirmed that very few
publications have addressed the topic of how to add a
treatment arm to an ongoing trial, and none have done
so either systematically or comprehensively.
Only a very small number of trials were identified to
have added arms in practice, indicating that although
this type of amendment may be advantageous, it is very
rarely implemented. Of the trials that had added an arm,
some failed to adequately address the statistical issues
and suffered from lack of power and difficulties of inter-
pretability. However, it is clear that this type of amend-
ment is desirable and advantageous, with the statistical
and logistical issues seeming by no means insurmountable.
Guidance is needed to allow amendments that add
new arms to existing trials to be made only with robust
statistical integrity. The benefits in cost, time and patient
resource savings from such amendments are clearly very
substantial; and therefore further methodological work
in this area is the subject of current research, so that the
addition of new arms to existing trials can, in the future,
be recommended and encouraged.
Appendix
Literature review search strategies by database
MEDLINE
1. Research Design/
2. exp Clinical Trials as Topic/
3. 1 or 2
Cohen et al. Trials  (2015) 16:179 Page 8 of 94. ((adaptive adj3 design*) or (adaptive adj3 method*)
or (adaptive adj3 trial*)).mp.
5. ((flexible adj3 design*) or (flexible adj3 method*) or
(flexible adj3 trial*)).mp.
6. ((multi?stage adj3 design) or (multi?stage adj3
method*) or (multi?stage adj3 trial*)).mp.
7. 4 or 5 or 6
8. ((adding or additional or incorporat* or extra) adj4
(arm* or treatment* or group* or therap* or randomi*
or hypothes*)).mp.
9. 3 and 7 and 8
EMBASE
1. Methodology/
2. exp “Clinical Trial (Topic)”/
3. 1 or 2
4. ((adaptive adj3 design*) or (adaptive adj3 method*)
or (adaptive adj3 trial*)).mp.
5. ((flexible adj3 design*) or (flexible adj3 method*) or
(flexible adj3 trial*)).mp.
6. ((multi?stage adj3 design) or (multi?stage adj3
method*) or (multi?stage adj3 trial*)).mp.
7. 4 or 5 or 6
8. ((adding or additional or incorporat* or extra) adj4
(arm* or treatment* or group* or therap* or randomi*
or hypothes*)).mp.
9. 3 and 7 and 8
Web of Knowledge (Web of Science)
Topic = (adaptive near/3 design* or adaptive near/3
method* or adaptive near/3 trial* or flexible near/3 design*
or flexible near/3 method* or flexible near/3 trial* or
multi$stage near/3 design* or multi$stage near/3 method*
or multi$stage near/3 trial*) AND Topic = ((adding or
additional or incorporat* or extra) near/4 (arm* or treat-
ment* or group* or therap* or randomi* or hypothes*))
Cochrane Library
1. MeSH descriptor: [Research Design] explode all trees
2. MeSH descriptor: [Clinical Trials as Topic] explode
all trees
3. 1 or 2
4. (adaptive near/3 design* or adaptive near/3 method* or
adaptive near/3 trial* or flexible near/3 design* or flexible
near/3 method* or flexible near/3 trial* or multi?stage
near/3 design* or multi?stage near/3 method* or
multi?stage near/3 trial*):ti,ab,kw and (adding or
additional or incorporat* or extra) near/4 (arm* or
treatment* or group* or therap* or randomi* or
hypothes*):ti,ab,kw (Word variations have been searched)
5. 3 and 4Proquest Scholarly Journals
(adaptive NEAR/3 design* OR adaptive NEAR/3
method* OR adaptive NEAR/3 trial* OR flexible NEAR/
3 design* OR flexible NEAR/3 method* OR flexible
NEAR/3 trial* OR multi*stage NEAR/3 design* OR
multi*stage NEAR/3 method* OR multi*stage NEAR/3
trial*
AND
all ((adding OR additional OR incorporat* OR extra)
NEAR/4 (arm* OR treatment* OR group* OR therap*
OR randomi* OR hypothes*))
AND
su. Exact (“research design (72950)” OR “research de-
sign” OR “clinical trials, phase ii as topic” OR “research
design (04701)” OR “clinical trials, phase iii as topic” OR
“clinical trials as topic” OR “clinical trials” OR “clinical
trials data monitoring committees”)
Additional limits - Source type: “Conference Papers &
Proceedings“ OR ”Scholarly Journals” OR “Dissertations
& Theses")
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